Drug discovery is long and winding, and riddled with high-cost failure at every turn. A newly unveiled Cambridge startup aims to streamline the process with a platform it’s calling “CRISPRomics” — and it has recruited some top-flight talent to lead the effort.

The two-year-old company — KSQ Therapeutics — just emerged from stealth, announcing a $76 million financing round and a new CEO: Dr. David Meeker, former chief executive of Genzyme. He stepped down from his post at the merged Sanofi-Genzyme (SNY) this past April.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy